Publications by authors named "Camille Taille"
Background: Hypereosinophilic syndromes (HES) are a heterogenous group of eosinophilic disorders. To date, only retrospective studies of limited sample-size and/or follow-up duration are available.
Methods: The COHESion study is a national prospective multicenter multidisciplinary cohort recruiting both adults or children with the spectrum of eosinophilic disorders (including reactive HE/HES [HE/HES-R], idiopathic HES [HES-I], lymphocytic HES [HES-L], neoplastic HE/HES [HE/HES-N], HE of unknown significance [HE-US], as well as IgG4-related disease [IgG4RD] or ANCA-negative eosinophilic granulomatosis with polyangiitis [EGPA] overlaps).
Introduction: Biologics provide significant benefits in asthma, reducing exacerbations and symptoms. Some biologics have shown promising results in small subgroups of patients with chronic obstructive pulmonary disease (COPD) and frequent exacerbations. Nevertheless, real-life data on the size of the COPD target population remain scarce.
View Article and Find Full Text PDFBackground: Chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma (SA) are 2 frequently coexisting conditions that are, in most cases, associated with eosinophilic inflammation. The concurrence of both diseases has a negative synergistic impact on disease severity and patients' health-related quality of life. Thus, a holistic, collaborative management of these patients is a critical unmet need.
View Article and Find Full Text PDFArticle Synopsis
- Interstitial lung disease (ILD) is a common complication in primary Sjögren's disease (pSD), but its long-term impact on lung function and patient outcomes is not well understood.
- A study of 73 pSD-ILD patients over an average of 9.3 years found that while lung function was generally stable, a significant portion experienced declines, particularly those with specific health characteristics.
- Key findings include two groups with different lung function trajectories: one with stable lung function and one with a decline of approximately 2.4% per year, where the latter group faced higher risks of death or needing a lung transplant.
Allergic asthma is the predominant phenotype among asthmatics. Although conventional pharmacotherapy is a central component in the management of asthma, it does not enable control of asthma symptoms in all patients. In recent decades, some uncontrolled asthmatic patients, especially those with allergic asthma, have benefited from biological therapies.
View Article and Find Full Text PDFBackground And Objective: Sarcoidosis can manifest with atypical findings on chest computed tomography (CT). Cysts are a rare manifestation of lung sarcoidosis. The aim of the study was to describe a series of patients with cystic sarcoidosis and their clinical-radiological characteristics and progression.
View Article and Find Full Text PDFArticle Synopsis
- Patients with severe eosinophilic asthma often switch from one biologic treatment to another when their current medication isn't effective, but it's unclear whether switching to a different class (anti-IL-4R) or another drug in the same class (anti-IL-5/5R) is better.
- In a study using data from a large asthma cohort, researchers compared the outcomes of patients who switched to either anti-IL-4R mAb or a different anti-IL-5/5R after not responding to their initial treatment.
- Results showed no significant difference in asthma control improvement at six months, but the anti-IL-4R group had a more notable reduction in corticosteroid use, suggesting it might
Exploring Definitions and Predictors of Response to Biologics for Severe Asthma.
J Allergy Clin Immunol Pract
September 2024
Background: Biologic effectiveness is often assessed as response, a term that eludes consistent definition. Identifying those most likely to respond in real-life has proven challenging.
Objective: To explore definitions of biologic responders in adults with severe asthma and investigate patient characteristics associated with biologic response.
Article Synopsis
- The study investigates how pre-biologic biomarker levels, specifically immunoglobulin E (IgE), blood eosinophil count (BEC), and fractional exhaled nitric oxide (FeNO), influence asthma treatment outcomes when patients start biologic therapy.
- Conducted across 23 countries with over 3750 patients, the research focused on changes in exacerbation rates, symptom control, and lung function about a year after starting treatment.
- Results showed that higher levels of BEC and FeNO were linked to significant improvements in lung function for specific biologic therapies, while IgE was not a strong predictor of treatment effectiveness.
Article Synopsis
- There is currently no agreed-upon definition for asthma remission in real life, and the factors that help patients achieve it after starting biologics are not well understood.
- A study analyzed data from 23 countries to see how many adults with severe asthma reached multidomain-defined remission after beginning biologic treatment, using specific criteria for remission.
- Results showed that less than a quarter of participants achieved full remission, with higher chances for those with fewer exacerbations, lower corticosteroid use, and better control and lung function before treatment, suggesting that early intervention is crucial for better outcomes.
Article Synopsis
- - The French RAMSES study compared severe asthma patients managed in tertiary referral centres (TRCs) versus secondary care centres (SCCs) to understand differences in patient characteristics and care practices.
- - A total of 2046 patients were included: 73.4% from TRCs and 26.6% from SCCs; key findings showed that TRC patients had more comorbidities but lower blood eosinophil counts and benefited more from educational programs and in-depth investigations.
- - The study concluded that asthma care trajectories and patient phenotypes varied significantly between TRCs and SCCs, emphasizing the need for standardized approaches to managing severe asthma.
Background: One of the major challenges in managing allergic bronchopulmonary aspergillosis remains consistent and reproducible assessment of response to treatment.
Research Question: What are the most relevant changes in CT scan parameters over time for assessing response to treatment?
Study Design And Methods: In this ancillary study of a randomized clinical trial (NebuLamB), patients with asthma with available CT scan and without exacerbation during a 4-month allergic bronchopulmonary aspergillosis exacerbation treatment period (corticosteroids and itraconazole) were included. Changed CT scan parameters were assessed by systematic analyses of CT scan findings at initiation and end of treatment.
Purpose: Severe asthma affects 5 to 10% of asthmatics and accounts for a large part of asthma-related morbidity and costs. The determinants of asthma severity are poorly understood. We tested the hypothesis that asthma severity was associated with 1) atopy and allergy and 2) markers associated with environmental exposure.
View Article and Find Full Text PDFIntro: An increased prevalence of serum anti-MCV antibody is observed in the serum of patients with idiopathic pulmonary fibrosis (IPF) but the clinical relevance of these antibodies is unknown.
Methods: Patients from our center with a diagnosis of IPF according to the 2018 ATS/ERS/JRS/ALAT guidelines and at least one anti-MCV assay available were selected. All patients were part of the prospective cohort European IPF registry and selected between 03/2010 and 03/2018.
Article Synopsis
- Previous studies on how comorbidities affect the effectiveness of biologic agents in asthma were limited in size and duration, lacking comparisons between different biologic classes.
- This cohort study analyzed data from the International Severe Asthma Registry across 21 countries to assess changes in asthma outcomes after starting biologic therapy in patients with type 2-related comorbidities.
- Results showed that patients with chronic rhinosinusitis (CRS) and nasal polyps (NPs) experienced significantly better outcomes, including fewer exacerbations and improved asthma control, while allergic rhinitis and atopic dermatitis did not influence therapy effectiveness.
Background: Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with biologics.
Purpose: We aim to describe asthma control and healthcare consumption of severe asthma patients treated with biologics.
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is often associated with glucocorticoid-dependent asthma and/or ear, nose and throat (ENT) manifestations. When immunosuppressants and/or mepolizumab are ineffective, dupilumab could be an option. We describe the safety and efficacy of off-label use of dupilumab in relapsing and/or refractory EGPA.
View Article and Find Full Text PDF